SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement With Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement With Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
SK Biopharmaceuticals and KIRAMS will seek to submit an Investigational New Drug application by 2027, as they leverage each other's resources to optimize their drug discovery efforts. SK Biopharmaceuticals said it could significantly reduce the time and cost of new drug development, with KIRAMS' researchers, facilities and equipment using the radioisotope, enabling the company to further accelerate in securing and expanding its RPT pipeline and capability.- SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments
- The two sides aim to submit an Investigational New Drug application by 2027, in line with SK Biopharmaceuticals' roadmap to strengthen its radiopharmaceutical therapy business
- SK Biopharmaceuticals further accelerates the expansion of its radiopharmaceutical therapy pipeline and capability, via strengthened internal resources and partnerships
- 韓國生物醫藥公司Sk Biopharmaceuticals和韓國放射醫學科學研究所合作，利用發射阿爾法粒子的放射性同位素鑥-225，共同發現和開發放射性藥物候選化合物，用於潛在的癌症治療。
- 雙方旨在根據Sk Biopharmaceuticals加強放射性藥物治療業務的路線圖，於2027年前提交新藥探索申請。
- Sk Biopharmaceuticals通過加強內部資源和合作夥伴關係，進一步加快了其放射性藥物治療管線和能力的擴展。
SEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ -- SK Biopharmaceuticals, a biotech company, announced that it has entered into an agreement with the Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea's premier research institution dedicated to the study and advancement of radiological and medical sciences, to collaborate on discovering and developing preclinical radiopharmaceutical drug candidates.
2024年11月18日，韓國首爾／PRNewswire／—生物科技公司Sk Biopharmaceuticals宣佈，已與韓國放射醫學科學研究所（KIRAMS）達成協議，韓國放射醫學科學研究所是韓國主要研究機構，致力於放射醫學科學的研究與推動，雙方合作共同發現和開發臨床前放射性藥物候選化合物。
This marks the first collaborative research agreement in which both sides will aim to discover radiopharmaceutical compounds and investigate novel oncological treatments, using actinium-225 (225Ac), an alpha-particle emitting radioisotope that selectively kills cancer cells. The research for radiopharmaceutical therapy (RPT) focuses on this application that has been gaining attention for its high potential in nuclear medicine.
這標誌着雙方的首個合作研究協議，雙方將致力於發現放射性藥物化合物，並探索新型腫瘤治療方法，使用能選擇性殺滅癌細胞的發射阿爾法粒子的放射性同位素鑥-225（225Ac）。放射性藥物治療（RPT）的研究專注於核醫學領域備受關注的這一應用。
SK Biopharmaceuticals has already initiated its 225Ac-based research as it secured a supply of the radioisotope from TerraPower Isotopes, a subsidiary of TerraPower, a nuclear innovation company whose investors include SK Biopharmaceuticals' parent SK Inc. and Bill Gates.
Sk Biopharmaceuticals已開始其基於225Ac的研究，因其從TerraPower Isotopes獲得了這種放射性同位素供應，TerraPower Isotopes是TerraPower的子公司，TerraPower是一家核創新公司，其投資者包括Sk Biopharmaceuticals的母公司Sk Inc.和比爾·蓋茨。
SK Biopharmaceuticals and KIRAMS will seek to submit an Investigational New Drug application by 2027, as they leverage each other's resources to optimize their drug discovery efforts. SK Biopharmaceuticals said it could significantly reduce the time and cost of new drug development, with KIRAMS' researchers, facilities and equipment using the radioisotope, enabling the company to further accelerate in securing and expanding its RPT pipeline and capability.
Sk Biopharmaceuticals和KIRAMS將利用彼此的資源，優化他們的藥物發現工作，力求在2027年前提交新藥探索申請。Sk Biopharmaceuticals表示，藉助KIRAMS的研究人員、設施和設備，使用該放射性同位素，可以顯著減少新藥研發的時間和成本，使公司進一步加速獲得和擴展其RPT管線和能力。
The agreement is in line with SK Biopharmaceuticals' so-called "RPT Roadmap" recently introduced to become a global leading RPT player by 2027, as the company will fortify its RPT business by discovering new drug compounds, extending supply and production capacities, and developing a tech platform, via strengthened internal assets and strategic partnerships.
該協議符合Sk生物製藥最近推出的「RPt路線圖」，目標是到2027年成爲全球領先的RPt參與者，該公司將通過發現新藥物化合物、擴展供應和生產能力以及開發技術平台來加強其RPt業務，通過加強內部資產和戰略合作伙伴關係。
In addition to the 225Ac supply agreement aligned with its roadmap, the company has in-licensed SKL35501 (FL-091) radiopharmaceutical compound targeting neurotensin receptor 1 (NTSR1) solid tumors.
除了與其路線圖一致的225Ac供應協議外，公司還已批准了瞄準神經犬飲水系統素受體1(NTSR1)實體瘤的SKL35501(FL-091)放射藥物化合物。
Jinkyung Lee, President of KIRAMS, stated, "Through this joint research agreement, we aim to take a leading role in developing innovative radiopharmaceutical therapeutics, in alignment with the Ministry of Science and ICT's strategic initiative to drive advancements in Radiation Biology. We look forward to contributing to the growth of the domestic radiopharmaceutical industry in close collaboration with SK Biopharmaceuticals."
KIRAMS總裁李真京表示：「通過這項聯合研究協議，我們旨在在開展創新性放射藥物治療方面發揮主導作用，配合科技部科技與信息通信部的戰略倡議推動放射生物學進展。我們期待與Sk生物製藥密切合作，爲國內放射藥物行業的增長做出貢獻。」
Donghoon Lee, CEO and President of SK Biopharmaceuticals, said "This agreement is one of key steps in enhancing SK Biopharmaceuticals' research capabilities. We will seek to spur SK Biopharmaceuticals to become a leading global RPT player through strengthened ties."
Sk生物製藥的首席執行官兼總裁李東勳表示：「該協議是增強Sk生物製藥研究能力的關鍵步驟之一。我們將致力於通過加強聯繫推動Sk生物製藥成爲全球領先的RPt參與者。」
About SK Biopharmaceuticals
關於Sk生物製藥
SK Biopharmaceuticals focuses on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts.
Sk生物製藥專注於中樞神經系統(CNS)和腫瘤治療的研究、開發和商業化。2017年，Sk生物製藥成立了一個研究中心，通過研究和開發努力進軍腫瘤領域。
SK Biopharmaceuticals is the first and only Korean company to independently develop and commercialize an antiseizure medication, cenobamate (brand name: XCOPRI) in the U.S. More than 100,000 patients have been treated globally with cenobamate, developed by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, Inc., since its launch in the U.S. in 2020. Cenobamate has successfully entered five major regions: North America, Europe, Asia, Central and South America, and the Middle East and North Africa.
Sk生物製藥是首家也是唯一一家獨立在美國研發和商業化抗癲癇藥物的韓國公司，其品牌爲XCOPRI的瑟諾巴酮。自2020年在美國推出以來，全球已有超過10萬患者接受了由Sk生物製藥及其美國子公司Sk Life Science, Inc.開發的瑟諾巴酮治療。瑟諾巴酮已成功進入北美、歐洲、亞洲、中南美洲以及中東北非五個主要地區。
The company also has a pipeline of eight compounds in development in both CNS disorders and oncology. Additionally, SK Biopharmaceuticals is focused on the discovery of new treatments in oncology. For more information, visit SK Biopharmaceuticals' website at , and SK Life Science's website at .
該公司還開發了八種化合物，用於中樞神經系統疾病和腫瘤的治療。此外，愛文思控股致力於在腫瘤領域發現新療法。欲了解更多信息，請訪問愛文思控股的網站，以及Sk Life Science的網站。
About Korea Institute of Radiological and Medical Sciences
關於韓國放射醫學科學研究所
As a premier institution dedicated to the intersection of science, technology, and healthcare, the Korea Institute of Radiological and Medical Sciences (KIRAMS) is at the forefront of radiation medicine innovation.
作爲致力於科學、科技和醫療交叉領域的頂尖機構，韓國放射醫學科學研究所（KIRAMS）位於放射醫學創新的前沿。
Ever since KIRAMS opened its doors as a radiation medicine research center in 1963, we have been contributing to the national development of science and technology, and to the promotion of the health of the people, based on our research in medical uses of radiation.
自1963年韓國放射醫學科學研究所作爲放射醫學研究中心開放以來，我們一直在基於放射醫學研究爲國家科技發展和人民健康促進做出貢獻。
By bringing the very first Cobalt-60 radiotherapy machine for cancer treatment to Korea in 1963, we were able to greatly increase the number of completely cured cancer patients. Following the restructuring of a cancer hospital in 1973, KIRAMS was leading domestic cancer treatment until the 1990s, by introducing diagnostic and treatment technologies that incorporated advanced science. In 2007, we became an independent institution, directly under the Ministry of Science and ICT, and since then we have established "Radiation Medicine" as a separate field of research and distinguished ourselves from other medical institutes by expanding the National Radiation Emergency Medical Center.
1963年，我們將第一臺鈷60放射治療機引入韓國，極大地增加了癌症完全治癒患者的數量。隨着1973年癌症醫院的重組，KIRAMS在1990年代之前一直領先於國內癌症治療，引入了融合先進科學的診斷和治療技術。2007年，我們成爲直屬於科技部的獨立機構，從那時起，我們將「放射醫學」確立爲一個獨立的研究領域，並通過擴建國家放射應急醫療中心，使自己與其他醫學研究機構區分開來。
And now, going beyond our original mission of defeating cancer, KIRAMS is evolving into a public institution committed to solving new problems for the country and for society, as well as for the benefit of the people. In other words, we are opening new horizons in radiation medicine by supporting specialized, research-centric hospitals engaged in advanced biomedical R&D, by consolidating research and detection of radiation in everyday life, which has recently become a social issue, and by establishing and operating the new Radioisotope Center for Pharmaceuticals to promote the research and use of radioisotopes for medical purposes.
如今，韓國放射醫學科學研究所已超越戰勝癌症的最初使命，發展爲致力於爲國家和社會解決新問題，造福於人民的公共機構。換句話說，我們通過支持從事先進生物醫藥研發的專業研究型醫院，整合放射檢測研究，將射線科技在日常生活中的應用也成爲社會問題，並設立並運營新的藥物放射同位素中心，促進射線同位素在醫學領域的研究和應用，開創了放射醫學的新局面。
Leveraging our extensive experience and our accomplishments, we here at the Korea Institute of Radiological and Medical Sciences will not rest but continually develop into the number one specialist institute for radiotherapy trusted by the people.
憑藉我們豐富的經驗和成就，在韓國放射醫學科學研究院，我們不會停止，將不斷髮展成爲備受人們信賴的放射治療專業機構。
For more information, visit .
欲了解更多信息，請訪問 。
SOURCE SK Biopharmaceuticals Co., Ltd
資訊 SK生物製藥有限公司
